TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

Therapeutic antibodies that block the programmed death-ligand 1 (PD-L1)/programmed death-1 (PD-1) pathway can induce robust and durable responses in patients with various cancers, including metastatic urothelial cancer (mUC)(1–5). However, these responses only occur in a subset of patients. Elucidat...

Descripción completa

Detalles Bibliográficos
Autores principales: Mariathasan, Sanjeev, Turley, Shannon J., Nickles, Dorothee, Castiglioni, Alessandra, Yuen, Kobe, Wang, Yulei, Kadel, Edward E., Koeppen, Hartmut, Astarita, Jillian L., Cubas, Rafael, Jhunjhunwala, Suchit, Banchereau, Romain, Yang, Yagai, Guan, Yinghui, Chalouni, Cecile, Ziai, James, Şenbabaoğlu, Yasin, Santoro, Stephen, Sheinson, Daniel, Hung, Jeffrey, Giltnane, Jennifer M., Pierce, Andrew K., Mesh, Kathryn, Lianoglou, Steve, Riegler, Johannes, Carano, Richard A. D., Eriksson, Pontus, Hoglund, Mattias, Somarriba, Loan, Halligan, Daniel L., van der Heijden, Michiel, Loriot, Yohann, Rosenberg, Jonathan E., Fong, Lawrence, Mellman, Ira, Chen, Daniel S., Green, Marjorie, Derleth, Christina, Fine, Gregg D., Hegde, Priti S., Bourgon, Richard, Powles, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6028240/
https://www.ncbi.nlm.nih.gov/pubmed/29443960
http://dx.doi.org/10.1038/nature25501

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6028240/
https://www.ncbi.nlm.nih.gov/pubmed/29443960
http://dx.doi.org/10.1038/nature25501

Ejemplares similares